Sökning: id:"swepub:oai:lup.lub.lu.se:440ce85f-649d-4313-8a49-3b503c733b74" >
Androgen Receptor i...
-
Niméus, EmmaLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Bröstcancerkirurgi,Forskargrupper vid Lunds universitet,Bröstcancer Proteogenomik,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Breast Cancer Surgery,Lund University Research Groups,Breast cancer Proteogenomics,Skåne University Hospital
(författare)
Androgen Receptor in Stage I-II Primary Breast Cancer -Prognostic Value and Distribution in Subgroups
- Artikel/kapitelEngelska2017
Förlag, utgivningsår, omfång ...
-
Anticancer Research USA Inc.2017
-
9 s.
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:440ce85f-649d-4313-8a49-3b503c733b74
-
https://lup.lub.lu.se/record/440ce85f-649d-4313-8a49-3b503c733b74URI
-
https://doi.org/10.21873/anticanres.12146DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
BACKGROUND/AIM: The value of androgen receptor (AR) in breast cancer has gained renewed interest as a prognostic and treatment predictive biomarker. The aims of this work were to study the associations and the prognostic value of AR in patients from two clinical cohorts.MATERIALS AND METHODS: Cohort 1 included 208 premenopausal, node-negative patients of whom 87% had received no adjuvant medical treatment; cohort 2 consisted of 263 patients with stage II disease who had all received 2 years of adjuvant tamoxifen. A semi-quantitative assessment of nuclear AR expression divided into five groups (0-1%, 2-10%, 11-50%, 51-75%, and 76-100%) was performed. Survival analyses, stratified by cohort, were performed using both a trend-test and a cut-off of >10% for positivity.RESULTS: A total of 76% of all patients were AR+, and 89%, 48%, and 23% of the estrogen receptor-positive, negative, and triple-negative, respectively. In Cox regression, stratified by cohort, AR divided into five groups was a prognostic factor for 5-year distant disease-free survival with a hazard ratio of 0.86 per step in fraction score (p=0.018). With a predefined cut-off at 10%, moderate evidence of an effect remained (Hazard Ratio=0.67, p=0.077). In multivariable analysis, AR did not retain an independent prognostic value.CONCLUSION: AR is a weak, however, not independent prognostic factor for distant metastasis. Although the prognostic value of AR may be questionable, the study identified a subset of AR-positive triple-negative patients as being potential candidates for AR-directed therapy for which further studies are warranted.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Folkesson, ElinLund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund OsteoArthritis Division - Clinical Epidemiology Unit,Forskargrupper vid Lunds universitet,Molekylär skelettbiologi,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups,Molecular Skeletal Biology,Skåne University Hospital(Swepub:lu)med-efs
(författare)
-
Nodin, BjörnLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Personlig patologi och cancerbehandling,Forskargrupper vid Lunds universitet,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Personalized Pathology & Cancer Therapy,Lund University Research Groups,Skåne University Hospital(Swepub:lu)immu-bnn
(författare)
-
Hartman, LindaLund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Individuell Bröstcancerbehandling,Forskargrupper vid Lunds universitet,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Personalized Breast Cancer Treatment,Lund University Research Groups,Skåne University Hospital(Swepub:lu)li3247we
(författare)
-
Klintman, MarieLund University,Lunds universitet,Tumörmikromiljö,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Tumor microenvironment,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)med-mkt
(författare)
-
Bröstcancer-genetikSektion I
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Anticancer research: Anticancer Research USA Inc.37:12, s. 6845-68531791-75300250-7005
Internetlänk
Hitta via bibliotek
Till lärosätets databas